Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT05375188

To Evaluate if Dexmedetomidine Infusion Provides Renal Protection in Patients Undergoing Coronary Artery Bypass Graft

To Evaluate if Dexmedetomidine Infusion Has a Role in Renal Protection in Patients Undergoing Coronary Artery Bypass Graft Surgery. A Randomized Control Trial

Sponsor: National Institute of Cardiovascular Diseases, Pakistan

Conditions Acute Kidney Injury

Interventions Dexmedetomidine Normal Saline

Updated 4 times since 2022 Last updated: May 11, 2022 Started: Aug 1, 2021 Primary completion: Jan 31, 2022 Completion: Jan 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Acute Kidney Injury, this trial is completed. The trial is conducted by National Institute of Cardiovascular Diseases, Pakistan and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2022 — Apr 2023 [monthly]

Completed PHASE2_PHASE3

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Cardiovascular Diseases, Pakistan

Data source: National Institute of Cardiovascular Diseases, Pakistan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan